• Zenas BioPharma will present Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress in London on June 4, 2026.
• The trial met its primary endpoint, showing a 56% reduction in flare risk versus placebo over 52 weeks (HR 0.443; p=0.0005).
• Obexelimab also delivered statistically significant improvements on key secondary measures, including time to first flare requiring rescue therapy, complete remission rate, and lower cumulative glucocorticoid rescue use.
• Safety data showed fewer grade 3 or higher adverse events versus placebo (11.3% vs 23.7%) with no new safety signals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190705PRIMZONEFULLFEED9722691) on May 19, 2026, and is solely responsible for the information contained therein.